Updates in Medicine
Selected clinical studies, interpreted with the outcomes, limitations and context that matter.
A Bayesian synthesis of four randomised trials suggests a high probability of reducing renal replacement therapy initiation, without establishing a short-term mortality benefit.
A clinical roundup of OSA treatment, AI echocardiography, pacing and cardiovascular prevention—with the trial populations, results and evidence limits kept in view.
Cardiovascular benefit and a renal safety signal with systolic targets below 120 versus below 140 mmHg: a clinical interpretation of the full OPTIMAL-STROKE trial.
In a small phase 2a DENV-3 challenge study, five of six participants in each once-weekly group had no evidence of infection; protection against naturally acquired dengue remains unproven.
How light-gated ion channels and optogenetics transformed neuroscience, from algal proteins to precise control of neural circuits.
The phase 3 TRIUMPH-1 trial evaluated once-weekly GIP–GLP-1–glucagon triple-receptor agonism in adults with obesity without diabetes.
A nationwide study links brief oral corticosteroid treatment with gastrointestinal bleeding, pneumonia and heart failure soon after initiation.
A French observational study found fewer major cardiovascular events with atenolol over two years—but no statistically significant mortality difference.
Phase 1 data suggest that one-time in-vivo PCSK9 editing can produce large and durable LDL-C reductions, although long-term safety and cardiovascular benefit remain uncertain.
A US cause-specific modelling analysis estimates how weekly alcohol intake and drinking pattern relate to lifetime mortality, morbidity and injury risk.
The randomised trial tested whether metformin provides cardiovascular protection beyond glucose lowering in HFrEF.
